| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 20 | 2024 | 4800 | 2.100 |
Why?
|
| Peritoneal Neoplasms | 8 | 2022 | 863 | 1.930 |
Why?
|
| Uterine Cervical Neoplasms | 20 | 2024 | 1903 | 1.920 |
Why?
|
| Carcinoma, Neuroendocrine | 15 | 2024 | 742 | 1.870 |
Why?
|
| Endometrial Neoplasms | 14 | 2023 | 1385 | 1.400 |
Why?
|
| Teratoma | 4 | 2022 | 248 | 1.230 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2023 | 327 | 1.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2022 | 346 | 0.900 |
Why?
|
| Leiomyoma | 1 | 2024 | 162 | 0.860 |
Why?
|
| Cervix Uteri | 9 | 2023 | 245 | 0.830 |
Why?
|
| Dysgerminoma | 1 | 2022 | 42 | 0.830 |
Why?
|
| Herpesvirus 4, Human | 4 | 2024 | 959 | 0.820 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2022 | 499 | 0.810 |
Why?
|
| Hysterectomy | 8 | 2024 | 652 | 0.810 |
Why?
|
| Asbestos | 1 | 2022 | 37 | 0.810 |
Why?
|
| PAX8 Transcription Factor | 3 | 2022 | 51 | 0.780 |
Why?
|
| Immunohistochemistry | 23 | 2022 | 7643 | 0.750 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2024 | 481 | 0.700 |
Why?
|
| Biomarkers, Tumor | 19 | 2022 | 10713 | 0.680 |
Why?
|
| Carcinoma | 7 | 2023 | 2610 | 0.680 |
Why?
|
| Endometriosis | 2 | 2023 | 232 | 0.670 |
Why?
|
| Diagnosis, Differential | 17 | 2024 | 4838 | 0.640 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 1740 | 0.600 |
Why?
|
| Mesothelioma | 1 | 2022 | 558 | 0.560 |
Why?
|
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2016 | 3 | 0.540 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 107 | 0.540 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2020 | 442 | 0.540 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 7919 | 0.520 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2022 | 155 | 0.510 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 124 | 0.490 |
Why?
|
| Female | 67 | 2024 | 148790 | 0.490 |
Why?
|
| Carcinoma, Papillary | 3 | 2012 | 566 | 0.480 |
Why?
|
| DNA Helicases | 1 | 2016 | 459 | 0.450 |
Why?
|
| Keratins | 3 | 2004 | 340 | 0.450 |
Why?
|
| Spleen | 1 | 2016 | 718 | 0.450 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2016 | 561 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 334 | 0.440 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 279 | 0.430 |
Why?
|
| PAX5 Transcription Factor | 1 | 2013 | 47 | 0.420 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2013 | 56 | 0.420 |
Why?
|
| Humans | 85 | 2024 | 270601 | 0.420 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1723 | 0.410 |
Why?
|
| Vulvar Neoplasms | 3 | 2021 | 235 | 0.410 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2021 | 172 | 0.410 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1068 | 0.400 |
Why?
|
| Adult | 43 | 2024 | 81960 | 0.390 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 22 | 0.390 |
Why?
|
| Uterine Cervical Diseases | 1 | 2011 | 24 | 0.390 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2003 | 381 | 0.390 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 517 | 0.380 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2012 | 557 | 0.380 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2017 | 50 | 0.380 |
Why?
|
| Middle Aged | 41 | 2024 | 90450 | 0.370 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2011 | 2312 | 0.370 |
Why?
|
| Duodenitis | 1 | 2011 | 16 | 0.370 |
Why?
|
| Syndecan-1 | 2 | 2008 | 51 | 0.330 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2008 | 23 | 0.320 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 417 | 0.300 |
Why?
|
| Stomach | 1 | 2011 | 396 | 0.300 |
Why?
|
| Aged | 28 | 2023 | 73534 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 5238 | 0.280 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3081 | 0.280 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 3435 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 2 | 2021 | 426 | 0.260 |
Why?
|
| Endometrium | 4 | 2020 | 457 | 0.250 |
Why?
|
| Young Adult | 15 | 2023 | 22219 | 0.240 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 2035 | 0.240 |
Why?
|
| Neoplasm Staging | 13 | 2024 | 14021 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 3 | 2023 | 1388 | 0.230 |
Why?
|
| Mucin-1 | 1 | 2004 | 158 | 0.230 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2004 | 176 | 0.220 |
Why?
|
| Predictive Value of Tests | 6 | 2022 | 4964 | 0.220 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 3107 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 339 | 0.220 |
Why?
|
| Retrospective Studies | 21 | 2024 | 39922 | 0.220 |
Why?
|
| Mesonephroma | 1 | 2023 | 17 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2008 | 551 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2016 | 296 | 0.220 |
Why?
|
| Viral Matrix Proteins | 1 | 2003 | 176 | 0.210 |
Why?
|
| Transcription Factors | 2 | 2016 | 5415 | 0.210 |
Why?
|
| CDX2 Transcription Factor | 1 | 2022 | 35 | 0.200 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2002 | 2 | 0.200 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2022 | 20 | 0.200 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 179 | 0.200 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 45 | 0.190 |
Why?
|
| Thyroid Neoplasms | 2 | 2012 | 1894 | 0.190 |
Why?
|
| Lung Transplantation | 2 | 2004 | 380 | 0.190 |
Why?
|
| Myofibroblasts | 1 | 2022 | 93 | 0.190 |
Why?
|
| Peritoneum | 1 | 2022 | 151 | 0.190 |
Why?
|
| Conservative Treatment | 1 | 2021 | 65 | 0.190 |
Why?
|
| Paget Disease, Extramammary | 1 | 2001 | 54 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 10402 | 0.180 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 98 | 0.180 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 1825 | 0.180 |
Why?
|
| Hirschsprung Disease | 2 | 2011 | 51 | 0.180 |
Why?
|
| Cysts | 1 | 2022 | 206 | 0.180 |
Why?
|
| Aged, 80 and over | 14 | 2023 | 31084 | 0.180 |
Why?
|
| Biopsy | 6 | 2022 | 3491 | 0.180 |
Why?
|
| Anal Canal | 1 | 2001 | 237 | 0.180 |
Why?
|
| Wolffian Ducts | 1 | 2020 | 24 | 0.180 |
Why?
|
| Ovary | 2 | 2020 | 686 | 0.170 |
Why?
|
| Homozygote | 1 | 2022 | 771 | 0.170 |
Why?
|
| Pathology, Clinical | 1 | 2021 | 129 | 0.170 |
Why?
|
| Education, Distance | 1 | 2021 | 100 | 0.170 |
Why?
|
| Keratin-7 | 3 | 2004 | 48 | 0.160 |
Why?
|
| Endometrial Hyperplasia | 1 | 2020 | 122 | 0.160 |
Why?
|
| Sequence Deletion | 1 | 2022 | 908 | 0.160 |
Why?
|
| RNA, Viral | 3 | 2011 | 715 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2010 | 690 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 2386 | 0.150 |
Why?
|
| Perineum | 1 | 2018 | 115 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2018 | 114 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 510 | 0.150 |
Why?
|
| Microsatellite Instability | 2 | 2016 | 408 | 0.140 |
Why?
|
| Multiple Myeloma | 2 | 2008 | 2325 | 0.140 |
Why?
|
| Adolescent | 10 | 2022 | 32684 | 0.140 |
Why?
|
| Pathology | 1 | 2018 | 102 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2022 | 578 | 0.140 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2018 | 121 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 656 | 0.140 |
Why?
|
| Carcinosarcoma | 1 | 2018 | 145 | 0.140 |
Why?
|
| Registries | 3 | 2023 | 2209 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 16719 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2003 | 1555 | 0.140 |
Why?
|
| Intermediate Filament Proteins | 2 | 2010 | 80 | 0.140 |
Why?
|
| Bartholin's Glands | 1 | 2016 | 5 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 7787 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1101 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 481 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2488 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4899 | 0.130 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 106 | 0.130 |
Why?
|
| B-Lymphocytes | 3 | 2011 | 1419 | 0.130 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 118 | 0.130 |
Why?
|
| Gynecology | 1 | 2018 | 233 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 586 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2189 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 521 | 0.130 |
Why?
|
| Proteins | 1 | 2003 | 2030 | 0.120 |
Why?
|
| Myometrium | 1 | 2015 | 82 | 0.120 |
Why?
|
| Treatment Outcome | 8 | 2022 | 33811 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 2434 | 0.120 |
Why?
|
| Male | 18 | 2016 | 128395 | 0.120 |
Why?
|
| Curriculum | 1 | 2021 | 911 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 5157 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 12038 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 639 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 235 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2022 | 9460 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 283 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 551 | 0.110 |
Why?
|
| Phenotype | 2 | 2016 | 6501 | 0.110 |
Why?
|
| Margins of Excision | 1 | 2016 | 315 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 3656 | 0.110 |
Why?
|
| Survival Rate | 6 | 2022 | 12527 | 0.110 |
Why?
|
| Antibodies | 1 | 2016 | 801 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1576 | 0.110 |
Why?
|
| Endoscopy | 1 | 2016 | 495 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2001 | 1240 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 5595 | 0.110 |
Why?
|
| Calcinosis | 1 | 2016 | 427 | 0.110 |
Why?
|
| Contrast Media | 2 | 2016 | 1505 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 2199 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 906 | 0.100 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2011 | 53 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4837 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1044 | 0.090 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1044 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 1174 | 0.090 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 420 | 0.090 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 243 | 0.090 |
Why?
|
| Meningioma | 1 | 2013 | 308 | 0.090 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.090 |
Why?
|
| Organ Transplantation | 2 | 2003 | 210 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 223 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 142 | 0.090 |
Why?
|
| Prognosis | 5 | 2023 | 22520 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 234 | 0.090 |
Why?
|
| Tracheal Neoplasms | 1 | 2010 | 44 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 298 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2010 | 184 | 0.080 |
Why?
|
| Ameloblastoma | 1 | 2009 | 16 | 0.080 |
Why?
|
| Cyclin D1 | 1 | 2012 | 591 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 15270 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 4053 | 0.080 |
Why?
|
| Trisomy | 1 | 2010 | 240 | 0.080 |
Why?
|
| Topotecan | 2 | 2022 | 248 | 0.080 |
Why?
|
| Metaplasia | 1 | 2011 | 387 | 0.080 |
Why?
|
| Genomics | 1 | 2020 | 2832 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 324 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1544 | 0.080 |
Why?
|
| Osteonectin | 1 | 2009 | 54 | 0.080 |
Why?
|
| Mandibular Neoplasms | 1 | 2009 | 77 | 0.080 |
Why?
|
| Neural Plate | 1 | 2008 | 10 | 0.080 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 150 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 841 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7912 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 16242 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2011 | 377 | 0.080 |
Why?
|
| Herpesvirus 8, Human | 1 | 2008 | 107 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2016 | 1210 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 9047 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 666 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2021 | 17075 | 0.070 |
Why?
|
| Mastocytosis, Systemic | 1 | 2008 | 119 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 2028 | 0.070 |
Why?
|
| HIV Infections | 2 | 2011 | 2155 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 1091 | 0.070 |
Why?
|
| HIV | 1 | 2008 | 236 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 4006 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 10267 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3557 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 818 | 0.070 |
Why?
|
| Thyroid Gland | 1 | 2008 | 366 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 367 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 529 | 0.070 |
Why?
|
| Bevacizumab | 2 | 2022 | 967 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1581 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 389 | 0.060 |
Why?
|
| Cisplatin | 2 | 2023 | 2499 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 6193 | 0.060 |
Why?
|
| Child | 5 | 2021 | 30558 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3464 | 0.060 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 2068 | 0.060 |
Why?
|
| Lewis X Antigen | 1 | 2004 | 38 | 0.060 |
Why?
|
| Colon | 3 | 2016 | 684 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3707 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2023 | 1716 | 0.060 |
Why?
|
| Glioma | 1 | 2015 | 1986 | 0.060 |
Why?
|
| Thiazoles | 1 | 2008 | 727 | 0.060 |
Why?
|
| Disease Progression | 3 | 2022 | 6867 | 0.060 |
Why?
|
| WT1 Proteins | 1 | 2004 | 107 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2003 | 8 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2003 | 22 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2003 | 38 | 0.060 |
Why?
|
| Appendiceal Neoplasms | 1 | 2006 | 251 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 255 | 0.050 |
Why?
|
| Mutation | 3 | 2020 | 15905 | 0.050 |
Why?
|
| SOXF Transcription Factors | 1 | 2023 | 29 | 0.050 |
Why?
|
| Lymphoma | 1 | 2011 | 1516 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 17855 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2360 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 4966 | 0.050 |
Why?
|
| CD79 Antigens | 1 | 2002 | 7 | 0.050 |
Why?
|
| Leukosialin | 1 | 2002 | 16 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2022 | 2105 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1344 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 485 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5776 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 149 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 843 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 189 | 0.050 |
Why?
|
| Biomarkers | 2 | 2011 | 5048 | 0.050 |
Why?
|
| Germinal Center | 1 | 2002 | 166 | 0.050 |
Why?
|
| Polyploidy | 1 | 2022 | 76 | 0.050 |
Why?
|
| Keratin-20 | 1 | 2001 | 43 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 207 | 0.050 |
Why?
|
| Conization | 1 | 2021 | 38 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 3205 | 0.050 |
Why?
|
| Hemorrhoids | 1 | 2001 | 14 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2002 | 85 | 0.050 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2003 | 192 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 1403 | 0.050 |
Why?
|
| Laparoscopy | 2 | 2021 | 1302 | 0.050 |
Why?
|
| Merkel cell polyomavirus | 1 | 2021 | 31 | 0.050 |
Why?
|
| Etoposide | 1 | 2023 | 907 | 0.050 |
Why?
|
| Ki-1 Antigen | 1 | 2002 | 186 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2010 | 3040 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 174 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 443 | 0.050 |
Why?
|
| Virtual Reality | 1 | 2021 | 37 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 123 | 0.040 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2020 | 24 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 51 | 0.040 |
Why?
|
| Premenopause | 1 | 2020 | 135 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 46 | 0.040 |
Why?
|
| Chromogranins | 1 | 2020 | 87 | 0.040 |
Why?
|
| Computer-Assisted Instruction | 1 | 2021 | 83 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2020 | 9281 | 0.040 |
Why?
|
| Carboplatin | 1 | 2023 | 880 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 7273 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 129 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 2177 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2002 | 286 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 13413 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2009 | 2768 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2024 | 2272 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 1341 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 1754 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 1260 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 881 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 930 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 1761 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2002 | 1420 | 0.040 |
Why?
|
| Time Factors | 3 | 2020 | 12971 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14638 | 0.030 |
Why?
|
| Platinum | 1 | 2016 | 142 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1930 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3671 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2016 | 128 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 1000 | 0.030 |
Why?
|
| Microspheres | 1 | 2016 | 234 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3345 | 0.030 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 241 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2597 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 482 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 682 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 631 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 321 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 61346 | 0.030 |
Why?
|
| Epithelium | 1 | 2016 | 786 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1931 | 0.030 |
Why?
|
| Receptors, LHRH | 1 | 2013 | 38 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 1435 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2300 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 173 | 0.030 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 381 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2004 | 288 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2358 | 0.020 |
Why?
|
| Calbindin 2 | 1 | 2011 | 43 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2016 | 1140 | 0.020 |
Why?
|
| Ganglia | 1 | 2011 | 25 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 676 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1608 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 709 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 854 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2008 | 3568 | 0.020 |
Why?
|
| Peripherins | 1 | 2010 | 5 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2356 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2016 | 1581 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6445 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 553 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2010 | 128 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2021 | 1442 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1704 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1547 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2016 | 1858 | 0.020 |
Why?
|
| Apoptosis | 1 | 2003 | 7755 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 5759 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4969 | 0.020 |
Why?
|
| DNA Probes | 1 | 2008 | 244 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 606 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5923 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2179 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 596 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 374 | 0.020 |
Why?
|
| Rectum | 1 | 2010 | 480 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1610 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 5673 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 314 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1489 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 7050 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 252 | 0.020 |
Why?
|
| Dasatinib | 1 | 2008 | 881 | 0.020 |
Why?
|
| Ohio | 1 | 2004 | 116 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4391 | 0.010 |
Why?
|
| Infant | 2 | 2010 | 13992 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 9041 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 2618 | 0.010 |
Why?
|
| Syndecans | 1 | 2002 | 24 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 200 | 0.010 |
Why?
|
| Neprilysin | 1 | 2002 | 60 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2002 | 58 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3582 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2002 | 126 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 374 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 1347 | 0.010 |
Why?
|
| Azacitidine | 1 | 2009 | 1218 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3658 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 477 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2002 | 278 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 5318 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 503 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 677 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6344 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 2657 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 15931 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5144 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8602 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 1276 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 5869 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 7232 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 1837 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 5825 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 4992 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 14876 | 0.010 |
Why?
|